Skip to content

The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients

The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01487473
Enrollment
49
Registered
2011-12-07
Start date
2011-12-31
Completion date
2013-11-30
Last updated
2014-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Meditation, Mindfulness, Attention, Chronic Pain, Depression, Anxiety, Stress, Acceptance, Pain intensity, Pain disability

Brief summary

The main purpose of this study is to determine the degree to which Mindfulness-Based Stress Reduction, a group-based psychological therapy that includes mindfulness meditation exercises, reduces depression, anxiety, stress, pain intensity, and interference of pain with daily life among adult chronic pain patients. The second purpose is to examine the role of attention in improving psychological and physical health for chronic pain patients.

Interventions

BEHAVIORALMindfulness-Based Stress Reduction

An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.

Sponsors

Mount Sinai Hospital, Canada
CollaboratorOTHER
Wasser Pain Management Centre
CollaboratorUNKNOWN
Rasch Foundation
CollaboratorUNKNOWN
York University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adult chronic pain patients who are proficient in English * Capable of interacting with others in a group setting * Capable of working with a computer

Exclusion criteria

* Alcohol or drug abuse (past history is acceptable as long as their situation has been stable for at least 3 months) * Psychiatric psychosis (patients who have a past history of schizophrenia are eligible as long as they are currently stable) * Current major depressive disorder * Current severe social phobia * At immediate risk for suicide * Cerebral lesions or tumors (unless medically and cognitively stable) * Neurological disease * Medically unstable * Cognitively unstable * Previously participated in a mindfulness meditation program

Design outcomes

Primary

MeasureTime frameDescription
Pain disability and AttentionBaseline, immediately following treatment, and at 3 months follow upChange in pain disability assessed by the Pain Disability Index (PDI). Change in attention assessed by an adapted version of the Change Blindness Task

Secondary

MeasureTime frameDescription
AnxietyBaseline, immediately following treatment, and at 3 months follow upChange in anxiety assessed by the Depression, Anxiety, and Stress Scale 21 (DASS-21)
StressBaseline, immediately following treatment, and at 3 months follow upChange in stress assessed by the Depression, Anxiety, and Stress Scale 21 (DASS-21)
DepressionBaseline, immediately following treatment, and at 3 months follow upChange in depression assessed by the Depression, Anxiety, and Stress Scale 21 (DASS-21)
AcceptanceBaseline, immediately following treatment, and at 3 months follow upChange in acceptance assessed by the Chronic Pain Acceptance Questionnaire (CPAQ)
Pain IntensityBaseline, immediately following treatment, and at 3 months follow upChange in pain intensity assessed by the Short-form McGill Pain Questionnaire (SF-MPQ-2).
MindfulnessBaseline, immediately following treatment, and at 3 months follow upChange in mindfulness assessed by the Five Facet Mindfulness Questionnaire (FFMQ) and Mindful Attention Awareness Scale (MAAS)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026